Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.

The New England journal of medicine（2023）

引用 2|浏览14

暂无评分

摘要

In patients with resectable NSCLC, perioperative durvalumab plus neoadjuvant chemotherapy was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone, with a safety profile that was consistent with the individual agents. (Funded by AstraZeneca; AEGEAN ClinicalTrials.gov number, NCT03800134.).

查看译文

关键词

non–small-cell non–small-cell lung cancer,durvalumab,lung cancer,perioperative

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要